YUTIQ: payments to doctors
Payments that named YUTIQ as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.8M
- Providers
- 2,638
- Transactions
- 10,109
- Average per transaction
- $281
The per-transaction average — $281 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,638 providers the average total is $1,077, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Eyepoint Pharmaceuticals US, Inc. | $1,948,514 | 68.6% |
| Alimera Sciences, Inc. | $810,792 | 28.5% |
| ANI Pharmaceuticals, Inc. | $82,421 | 2.9% |